Buscar
Mostrando ítems 1-10 de 10
Sex‐ and Age‐Related Differences in the Management and Outcomes of Chronic Heart Failure: an Analysis of Patients from the ESC HFA EORP Heart Failure Long‐Term Registry
(Willey, 2019-12-20)
[Abstract]
Aims.
This study aimed to assess age‐ and sex‐related differences in management and 1‐year risk for all‐cause mortality and hospitalization in chronic heart failure (HF) patients.
Methods and results.
Of ...
Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes – from the ESC-HFA EORP Heart Failure Long-Term Registry
(European Society of Cardiology, 2023-04-27)
[Abstract] Aims: To comprehensively assess hyponatraemia in acute heart failure (AHF) regarding prevalence, associations, hospital course, and post-discharge outcomes.
Methods and results: Of 8298 patients in the European ...
A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry
(Wiley, 2021-12-27)
[Abstract] Aims: To perform a comprehensive characterization of acute heart failure (AHF) with preserved (HFpEF), versus mildly reduced (HFmrEF) versus reduced ejection fraction (HFrEF).
Methods and results: Of 5951 ...
Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry
(Wiley, 2017-04-06)
[Abstract] AIMS: The objectives of the present study were to describe epidemiology and outcomes in ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and to identify predictors ...
Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry
(Willey Online Library, 2020-04-01)
[Abstract]
Aims. Guidelines recommend down-titration of loop diuretics (LD) once euvolaemia is achieved. In outpatients with heart
failure (HF), we investigated LD dose changes in daily cardiology practice, agreement ...
Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry
(Wiley Online Library, 2020-07-02)
[Abstract]
Aims.
In hospitalized patients with a clinical diagnosis of acute heart failure (HF) with preserved ejection fraction (HFpEF), the aims of this study were (i) to assess the proportion meeting the 2016 European ...
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry
(Oxford, 2018-10-15)
[Abstract] Aim. To investigate the characteristics long-term prognostic implications (up to ∼2.2 years) of atrial fibrillation (AF) compared to sinus rhythm (SR), between acute and chronic heart failure (HF) with reduced ...
Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data From 9222 Chronic Heart Failure Patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
(Willey Online Library, 2020-04-03)
[Abstract]
Aims.
We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death ...
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world
(Wiley, 2019-05-27)
[Abstract] Aims: To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug ...